Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278915 · ClinicalTrials.gov registry record · Phase 2
Faslodex in McCune-Albright Syndrome
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00278915 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT00278915, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with McCune-Albright syndrome (MAS)
Interventions
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-01-31 |
| Est. Completion | 2023-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00278915
The ClinicalTrials.gov registry entry for NCT00278915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fulvestrant is the first listed.
NCT00278915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00278915 about?
NCT00278915 is a clinical study titled "Faslodex in McCune-Albright Syndrome". The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with McCune-Albright syndrome (MAS)
What is the current status of trial NCT00278915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-01-31. Estimated completion is 2023-07-20.
What interventions are being tested in trial NCT00278915?
The interventions under investigation include: Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00278915?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.